IRIS - Res&Arch Institutional Research Information System - Research & Archive

SALVADORI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.721
AS - Asia 1.302
EU - Europa 1.233
SA - Sud America 237
AF - Africa 48
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.672
SG - Singapore 559
IT - Italia 497
BR - Brasile 194
CN - Cina 163
HK - Hong Kong 157
IE - Irlanda 151
RU - Federazione Russa 105
KR - Corea 94
DE - Germania 84
VN - Vietnam 76
FR - Francia 69
NL - Olanda 52
GB - Regno Unito 47
BD - Bangladesh 43
IN - India 42
SE - Svezia 39
FI - Finlandia 37
AT - Austria 30
TR - Turchia 29
CA - Canada 24
RO - Romania 24
JP - Giappone 21
IQ - Iraq 20
PH - Filippine 19
PL - Polonia 17
ES - Italia 16
ZA - Sudafrica 16
BE - Belgio 13
CO - Colombia 13
UA - Ucraina 13
AR - Argentina 10
CH - Svizzera 10
PK - Pakistan 10
MX - Messico 8
SA - Arabia Saudita 8
AU - Australia 7
EC - Ecuador 7
IR - Iran 7
EG - Egitto 6
ID - Indonesia 6
MA - Marocco 6
TN - Tunisia 6
UZ - Uzbekistan 6
MD - Moldavia 5
TW - Taiwan 5
CL - Cile 4
CZ - Repubblica Ceca 4
IL - Israele 4
JO - Giordania 4
KH - Cambogia 4
LB - Libano 4
MY - Malesia 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
KG - Kirghizistan 3
LT - Lituania 3
OM - Oman 3
PA - Panama 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
NI - Nicaragua 2
NP - Nepal 2
PE - Perù 2
PY - Paraguay 2
UY - Uruguay 2
AM - Armenia 1
CV - Capo Verde 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
IS - Islanda 1
ML - Mali 1
MR - Mauritania 1
MW - Malawi 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
VC - Saint Vincent e Grenadine 1
Totale 4.550
Salva come PNG Salva come JPEG
Città #
Singapore 449
Chandler 191
San Jose 184
Dublin 147
Hong Kong 147
Perugia 136
Ashburn 113
Santa Clara 66
Boardman 58
San Mateo 56
The Dalles 47
Los Angeles 42
Moscow 42
Beijing 39
Lauterbourg 38
Altamura 34
Ann Arbor 32
Redmond 31
New York 30
Turin 29
Dearborn 28
Medford 28
Munich 28
Princeton 27
Seoul 27
Vienna 26
Ho Chi Minh City 23
São Paulo 22
Wilmington 22
Andover 20
Bucharest 20
Bologna 19
Lawrence 18
Seongnam-si 18
Orem 14
Tokyo 14
Brussels 13
Milan 13
Piscataway 13
Dallas 12
Falkenstein 12
Hanoi 12
Warsaw 12
Amsterdam 11
Denver 11
Falls Church 11
Boston 10
Johannesburg 10
London 10
Montreal 10
Nuremberg 10
Turku 10
Cebu City 9
Istanbul 9
Parma 9
Rome 9
Atlanta 8
Baghdad 8
Brooklyn 8
Council Bluffs 8
Frankfurt am Main 8
Groningen 8
Helsinki 8
Toronto 8
Chennai 7
Da Nang 7
Houston 7
Mumbai 7
Phoenix 7
Redwood City 7
Seodaemun-gu 7
Brasília 6
Collazzone 6
Des Moines 6
Florence 6
Glasgow 6
Incheon 6
Norwalk 6
Saint Petersburg 6
San Francisco 6
Cairo 5
Columbus 5
Dhaka 5
Dong Ket 5
Hefei 5
Stockholm 5
Ankara 4
City of London 4
Jakarta 4
Jinju 4
Karaj 4
Konya 4
Lahore 4
Mainz 4
Naples 4
Olomouc 4
Paris 4
Pavia 4
Phnom Penh 4
Raisio 4
Totale 2.734
Salva come PNG Salva come JPEG
Nome #
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 275
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 198
Histological muscle characterization in hypertrophied Marchigiana cattle breed 174
Intraperitoneal injection of microencapsulated Sertoli cells restores muscle morphology and performance in dystrophic mice 173
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 152
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 149
RAGE in the pathophysiology of skeletal muscle. 147
Generation of an mdx/Ager–/– double mutant mouse. Preliminary data on skeletal muscle architecture. 141
Equisetum arvense standardized extract hinders age-related sarcopenia 139
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 138
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 136
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 136
Natural products to counteract muscle atrophy 133
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 131
Effects of intraperitoneal injection of microencapsulated Sertoli cells on chronic and presymptomatic dystrophic mice 129
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 129
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 128
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 127
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 124
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 111
Mdx/Ager–/– mice show reduced muscle necrosis and inflammation compared with mdx mice 110
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 108
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 107
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 107
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 107
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 105
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 105
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 102
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 102
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 101
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 99
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 95
The receptor RAGE: a potential molecular target in cancer cachexia 93
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 88
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 76
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer 74
Sertoli cells improve myogenic differentiation, reduce fibrogenic markers, and induce utrophin expression in human dmd myoblasts 66
Sertoli cells have promyogenic and antifibrotic effects, and induce utrophin expression in human DMD myotubes with different mutations in a heregulin β1/ErbB2/ERK1/2-dependent manner 52
Diet-Derived Advanced Glycation End-Products (AGEs) Induce Muscle Wasting In Vitro, and a Standardized Vaccinium macrocarpon Extract Restrains AGE Formation and AGE-Dependent C2C12 Myotube Atrophy 13
Totale 4.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.531
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.531
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022290 3 40 9 17 6 8 8 75 10 32 43 39
2022/2023548 30 104 3 49 44 61 1 25 198 2 22 9
2023/2024286 15 23 5 23 8 21 80 4 4 14 22 67
2024/20251.143 43 83 134 70 112 55 113 118 146 68 143 58
2025/20261.847 102 88 73 216 229 158 309 115 175 151 175 56
2026/2027137 137 0 0 0 0 0 0 0 0 0 0 0
Totale 4.680